Abstract
Summary
Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.
The global market for Bacteriophage Therapy was estimated to be worth US$ 32 million in 2023 and is forecast to a readjusted size of US$ 62 million by 2030 with a CAGR of 9.6% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bacteriophage Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Bacteriophage Therapy by region & country, by Type, and by Application.
The Bacteriophage Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bacteriophage Therapy.
Market Segmentation
By Company
Armata Pharmaceuticals, Inc.
Eliava Biopreparations Ltd.
Pherecydes Pharma
Intralytix, Inc.
Phagelux Inc.
Nextbiotics
InnoPhage, Ltd
Locus Biosciences, Inc.
TechnoPhage
Eligo Bioscience SA
Phagomed Biopharma GmbH.
PhagePro, Inc.
Adaptive Phage Therapeutics, Inc.
EnBiotix, Inc.
Intodeworld, Inc.
BiomX Ltd.
Phi Therapeutics
Fixed-phage Ltd.
Micreos BV
ContraFect Corporation
Segment by Type:
Oral
Topical
Parenteral
Segment by Application
Organ Transplantation
Bacterial Infections
Alcoholic Hepatitis
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Bacteriophage Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Bacteriophage Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Bacteriophage Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Bacteriophage Therapy was estimated to be worth US$ 32 million in 2023 and is forecast to a readjusted size of US$ 62 million by 2030 with a CAGR of 9.6% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bacteriophage Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Bacteriophage Therapy by region & country, by Type, and by Application.
The Bacteriophage Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bacteriophage Therapy.
Market Segmentation
By Company
Armata Pharmaceuticals, Inc.
Eliava Biopreparations Ltd.
Pherecydes Pharma
Intralytix, Inc.
Phagelux Inc.
Nextbiotics
InnoPhage, Ltd
Locus Biosciences, Inc.
TechnoPhage
Eligo Bioscience SA
Phagomed Biopharma GmbH.
PhagePro, Inc.
Adaptive Phage Therapeutics, Inc.
EnBiotix, Inc.
Intodeworld, Inc.
BiomX Ltd.
Phi Therapeutics
Fixed-phage Ltd.
Micreos BV
ContraFect Corporation
Segment by Type:
Oral
Topical
Parenteral
Segment by Application
Organ Transplantation
Bacterial Infections
Alcoholic Hepatitis
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Bacteriophage Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Bacteriophage Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Bacteriophage Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Bacteriophage Therapy Product Introduction
1.2 Global Bacteriophage Therapy Market Size Forecast
1.3 Bacteriophage Therapy Market Trends & Drivers
1.3.1 Bacteriophage Therapy Industry Trends
1.3.2 Bacteriophage Therapy Market Drivers & Opportunity
1.3.3 Bacteriophage Therapy Market Challenges
1.3.4 Bacteriophage Therapy Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Bacteriophage Therapy Players Revenue Ranking (2023)
2.2 Global Bacteriophage Therapy Revenue by Company (2019-2024)
2.3 Key Companies Bacteriophage Therapy Manufacturing Base Distribution and Headquarters
2.4 Key Companies Bacteriophage Therapy Product Offered
2.5 Key Companies Time to Begin Mass Production of Bacteriophage Therapy
2.6 Bacteriophage Therapy Market Competitive Analysis
2.6.1 Bacteriophage Therapy Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Bacteriophage Therapy Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bacteriophage Therapy as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oral
3.1.2 Topical
3.1.3 Parenteral
3.2 Global Bacteriophage Therapy Sales Value by Type
3.2.1 Global Bacteriophage Therapy Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Bacteriophage Therapy Sales Value, by Type (2019-2030)
3.2.3 Global Bacteriophage Therapy Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Organ Transplantation
4.1.2 Bacterial Infections
4.1.3 Alcoholic Hepatitis
4.1.4 Other
4.2 Global Bacteriophage Therapy Sales Value by Application
4.2.1 Global Bacteriophage Therapy Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Bacteriophage Therapy Sales Value, by Application (2019-2030)
4.2.3 Global Bacteriophage Therapy Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Bacteriophage Therapy Sales Value by Region
5.1.1 Global Bacteriophage Therapy Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Bacteriophage Therapy Sales Value by Region (2019-2024)
5.1.3 Global Bacteriophage Therapy Sales Value by Region (2025-2030)
5.1.4 Global Bacteriophage Therapy Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Bacteriophage Therapy Sales Value, 2019-2030
5.2.2 North America Bacteriophage Therapy Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Bacteriophage Therapy Sales Value, 2019-2030
5.3.2 Europe Bacteriophage Therapy Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Bacteriophage Therapy Sales Value, 2019-2030
5.4.2 Asia Pacific Bacteriophage Therapy Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Bacteriophage Therapy Sales Value, 2019-2030
5.5.2 South America Bacteriophage Therapy Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Bacteriophage Therapy Sales Value, 2019-2030
5.6.2 Middle East & Africa Bacteriophage Therapy Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Bacteriophage Therapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Bacteriophage Therapy Sales Value
6.3 United States
6.3.1 United States Bacteriophage Therapy Sales Value, 2019-2030
6.3.2 United States Bacteriophage Therapy Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Bacteriophage Therapy Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Bacteriophage Therapy Sales Value, 2019-2030
6.4.2 Europe Bacteriophage Therapy Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Bacteriophage Therapy Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Bacteriophage Therapy Sales Value, 2019-2030
6.5.2 China Bacteriophage Therapy Sales Value by Type (%), 2023 VS 2030
6.5.3 China Bacteriophage Therapy Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Bacteriophage Therapy Sales Value, 2019-2030
6.6.2 Japan Bacteriophage Therapy Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Bacteriophage Therapy Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Bacteriophage Therapy Sales Value, 2019-2030
6.7.2 South Korea Bacteriophage Therapy Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Bacteriophage Therapy Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Bacteriophage Therapy Sales Value, 2019-2030
6.8.2 Southeast Asia Bacteriophage Therapy Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Bacteriophage Therapy Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Bacteriophage Therapy Sales Value, 2019-2030
6.9.2 India Bacteriophage Therapy Sales Value by Type (%), 2023 VS 2030
6.9.3 India Bacteriophage Therapy Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Armata Pharmaceuticals, Inc.
7.1.1 Armata Pharmaceuticals, Inc. Profile
7.1.2 Armata Pharmaceuticals, Inc. Main Business
7.1.3 Armata Pharmaceuticals, Inc. Bacteriophage Therapy Products, Services and Solutions
7.1.4 Armata Pharmaceuticals, Inc. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.1.5 Armata Pharmaceuticals, Inc. Recent Developments
7.2 Eliava Biopreparations Ltd.
7.2.1 Eliava Biopreparations Ltd. Profile
7.2.2 Eliava Biopreparations Ltd. Main Business
7.2.3 Eliava Biopreparations Ltd. Bacteriophage Therapy Products, Services and Solutions
7.2.4 Eliava Biopreparations Ltd. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.2.5 Eliava Biopreparations Ltd. Recent Developments
7.3 Pherecydes Pharma
7.3.1 Pherecydes Pharma Profile
7.3.2 Pherecydes Pharma Main Business
7.3.3 Pherecydes Pharma Bacteriophage Therapy Products, Services and Solutions
7.3.4 Pherecydes Pharma Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.3.5 Intralytix, Inc. Recent Developments
7.4 Intralytix, Inc.
7.4.1 Intralytix, Inc. Profile
7.4.2 Intralytix, Inc. Main Business
7.4.3 Intralytix, Inc. Bacteriophage Therapy Products, Services and Solutions
7.4.4 Intralytix, Inc. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.4.5 Intralytix, Inc. Recent Developments
7.5 Phagelux Inc.
7.5.1 Phagelux Inc. Profile
7.5.2 Phagelux Inc. Main Business
7.5.3 Phagelux Inc. Bacteriophage Therapy Products, Services and Solutions
7.5.4 Phagelux Inc. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.5.5 Phagelux Inc. Recent Developments
7.6 Nextbiotics
7.6.1 Nextbiotics Profile
7.6.2 Nextbiotics Main Business
7.6.3 Nextbiotics Bacteriophage Therapy Products, Services and Solutions
7.6.4 Nextbiotics Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.6.5 Nextbiotics Recent Developments
7.7 InnoPhage, Ltd
7.7.1 InnoPhage, Ltd Profile
7.7.2 InnoPhage, Ltd Main Business
7.7.3 InnoPhage, Ltd Bacteriophage Therapy Products, Services and Solutions
7.7.4 InnoPhage, Ltd Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.7.5 InnoPhage, Ltd Recent Developments
7.8 Locus Biosciences, Inc.
7.8.1 Locus Biosciences, Inc. Profile
7.8.2 Locus Biosciences, Inc. Main Business
7.8.3 Locus Biosciences, Inc. Bacteriophage Therapy Products, Services and Solutions
7.8.4 Locus Biosciences, Inc. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.8.5 Locus Biosciences, Inc. Recent Developments
7.9 TechnoPhage
7.9.1 TechnoPhage Profile
7.9.2 TechnoPhage Main Business
7.9.3 TechnoPhage Bacteriophage Therapy Products, Services and Solutions
7.9.4 TechnoPhage Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.9.5 TechnoPhage Recent Developments
7.10 Eligo Bioscience SA
7.10.1 Eligo Bioscience SA Profile
7.10.2 Eligo Bioscience SA Main Business
7.10.3 Eligo Bioscience SA Bacteriophage Therapy Products, Services and Solutions
7.10.4 Eligo Bioscience SA Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.10.5 Eligo Bioscience SA Recent Developments
7.11 Phagomed Biopharma GmbH.
7.11.1 Phagomed Biopharma GmbH. Profile
7.11.2 Phagomed Biopharma GmbH. Main Business
7.11.3 Phagomed Biopharma GmbH. Bacteriophage Therapy Products, Services and Solutions
7.11.4 Phagomed Biopharma GmbH. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.11.5 Phagomed Biopharma GmbH. Recent Developments
7.12 PhagePro, Inc.
7.12.1 PhagePro, Inc. Profile
7.12.2 PhagePro, Inc. Main Business
7.12.3 PhagePro, Inc. Bacteriophage Therapy Products, Services and Solutions
7.12.4 PhagePro, Inc. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.12.5 PhagePro, Inc. Recent Developments
7.13 Adaptive Phage Therapeutics, Inc.
7.13.1 Adaptive Phage Therapeutics, Inc. Profile
7.13.2 Adaptive Phage Therapeutics, Inc. Main Business
7.13.3 Adaptive Phage Therapeutics, Inc. Bacteriophage Therapy Products, Services and Solutions
7.13.4 Adaptive Phage Therapeutics, Inc. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.13.5 Adaptive Phage Therapeutics, Inc. Recent Developments
7.14 EnBiotix, Inc.
7.14.1 EnBiotix, Inc. Profile
7.14.2 EnBiotix, Inc. Main Business
7.14.3 EnBiotix, Inc. Bacteriophage Therapy Products, Services and Solutions
7.14.4 EnBiotix, Inc. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.14.5 EnBiotix, Inc. Recent Developments
7.15 Intodeworld, Inc.
7.15.1 Intodeworld, Inc. Profile
7.15.2 Intodeworld, Inc. Main Business
7.15.3 Intodeworld, Inc. Bacteriophage Therapy Products, Services and Solutions
7.15.4 Intodeworld, Inc. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.15.5 Intodeworld, Inc. Recent Developments
7.16 BiomX Ltd.
7.16.1 BiomX Ltd. Profile
7.16.2 BiomX Ltd. Main Business
7.16.3 BiomX Ltd. Bacteriophage Therapy Products, Services and Solutions
7.16.4 BiomX Ltd. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.16.5 BiomX Ltd. Recent Developments
7.17 Phi Therapeutics
7.17.1 Phi Therapeutics Profile
7.17.2 Phi Therapeutics Main Business
7.17.3 Phi Therapeutics Bacteriophage Therapy Products, Services and Solutions
7.17.4 Phi Therapeutics Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.17.5 Phi Therapeutics Recent Developments
7.18 Fixed-phage Ltd.
7.18.1 Fixed-phage Ltd. Profile
7.18.2 Fixed-phage Ltd. Main Business
7.18.3 Fixed-phage Ltd. Bacteriophage Therapy Products, Services and Solutions
7.18.4 Fixed-phage Ltd. Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.18.5 Fixed-phage Ltd. Recent Developments
7.19 Micreos BV
7.19.1 Micreos BV Profile
7.19.2 Micreos BV Main Business
7.19.3 Micreos BV Bacteriophage Therapy Products, Services and Solutions
7.19.4 Micreos BV Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.19.5 Micreos BV Recent Developments
7.20 ContraFect Corporation
7.20.1 ContraFect Corporation Profile
7.20.2 ContraFect Corporation Main Business
7.20.3 ContraFect Corporation Bacteriophage Therapy Products, Services and Solutions
7.20.4 ContraFect Corporation Bacteriophage Therapy Revenue (US$ Million) & (2019-2024)
7.20.5 ContraFect Corporation Recent Developments
8 Industry Chain Analysis
8.1 Bacteriophage Therapy Industrial Chain
8.2 Bacteriophage Therapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Bacteriophage Therapy Sales Model
8.5.2 Sales Channel
8.5.3 Bacteriophage Therapy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer